CATX
Fiscal year ends June Quarters are offset from the calendar — Q1 is Jul–Sep

Perspective Therapeutics, Inc. is a clinical-stage radiopharmaceutical company developing targeted alpha-particle therapies (TATs) for the treatment of cancer. The company utilizes the alpha-emitting isotope Lead-212 (212Pb) conjugated to high-affinity targeting peptides to deliver radiation directly to cancer cells, paired with complementary imaging diagnostics using Lead-203 (203Pb) to enable a theranostic approach. Its pipeline includes VMT-α-NET for neuroendocrine tumors, VMT01 for melanoma, and PSV359 for solid tumors expressing fibroblast activation protein, all of which are in Phase 1/2a trials in the U.S. The company operates a proprietary manufacturing and supply infrastructure using 212Pb generator technologies to produce patient-ready product candidates. Perspective Therapeutics was formed in 2023 following the merger of Viewpoint Molecular Targeting, Inc. and Isoray, Inc.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage perspectivetherapeutics.com
Sector Healthcare IR page perspectivetherapeutics.com/investors
Tags
radiopharmaceuticals, targeted alpha therapy, theranostics, oncology, neuroendocrine tumors, melanoma, solid tumors, lead-212, peptide conjugates, clinical-stage, VMT-α-NET, VMT01, PSV359, Viewpoint Molecular Targeting Inc., Isoray Inc.
Press page perspectivetherapeutics.com/newsroom/press-releases

Metrics

Valuation  
Market cap $ 95.667M
Market cap (USD) $ 95.667M
P/E -0.67
PEG —
P/BV 0.32
P/S 66.71
P/OCF -0.88
P/FCF -0.69
Dividend yield —
Turnover / mcap —
Returns  
ROE -41.4%
ROI -49.4%
ROIC -40.8%
Profit margin —
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock —
Diluting (TTM) Yes
Debt/Equity 0.54%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 75
Quality score -73.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2009 FY 2008 FY 2007 FY 2001 FY 2000 FY 1999 FY 1998
Revenue — — 1.434M 10.795M 10.053M 9.68M 7.314M 5.923M 4.761M 4.769M 4.607M 4.219M 4.525M 5.071M 5.418M 7.159M 5.738M — — — —
Net profit -103.121M -79.279M -46.508M -7.272M -3.387M -3.446M -5.144M -6.7M -6.162M -4.711M -3.681M -5.959M -3.857M -3.489M -6.161M -8.558M -9.605M 235.11K -65.649K 1.825M -139.549K
Free cash flow -95.233M -72.708M -37.985M -7.976M -3.218M -3.914M -5.493M -6.049M -6.261M -4.363M -3.655M -3.247M -3.063M -2.503M -4.007M -10.816M -9.648M — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2009 FY 2008 FY 2007 FY 2001 FY 2000 FY 1999 FY 1998
Share price 2.75 3.19 0.4 0.31 0.8 0.56 0.41 0.45 0.63 0.87 1.48 3.12 0.48 1.02 — — — — — — —
Price performance 12m -0.14 6.94 0.63 -0.61 0.44 0.36 -0.09 -0.28 -0.28 -0.41 -0.53 5.46 -0.53 — — — — — — — —

Filed figures

Figure Jun 2021 Jun 2022 Dec 2022 Jun 2023 Dec 2023 Jun 2024 Dec 2024 Jun 2025 Dec 2025 Jun 2026
Balance sheet detail
Trade receivables (USD) 2.01M 1.61M 1.36M 1.11M 1.17M 142,000 116,000 225,000 6,000 269,000
↳ YoY growth -1.5% -20.1% -17.2% -30.8% -14.5% -87.2% -90.0% +58.5% -94.8% +19.6%
↳ 5y CAGR +27.2% +17.2% +6.7% -1.4% +1.0% -34.2% -39.3% -35.7% -67.8% -33.1%
Lease liabilities (USD) 776,000 524,000 392,000 805,000 826,000 2.17M 2.39M 1.92M 1.63M 2.37M
Cash and deposits (USD) 63.8M 55.9M 21M 28.3M 9.24M 252M 61.6M 28.8M 30.6M 48.5M
Intangible assets (USD) 130,000 107,000 86,000 50M 354,000 — 279,000 — 362,000 —
Right-of-use assets (USD) 768,000 512,000 378,000 805,000 747,000 2.02M 2.22M 1.77M 1.5M 2.2M
Cash flow detail
Operating cash flow (USD) -2.84M -7.71M -10.4M — -36.9M — -18.3M — -82.5M —
Purchases of property, plant and equipment (USD) -381,000 -266,000 -282,000 — -1.07M — -54.4M — -12.7M —
Purchases of intangible assets (USD) -30,000 -18,000 -18,000 — -18,000 — — — — —
Change in receivables (cash effect) (USD) 31,000 405,000 284,000 — -426,000 — 1.05M — 110,000 —
Change in inventories (cash effect) (USD) -274,000 -2.67M -2M — 359,000 — — — — —
Change in payables (cash effect) (USD) 76,000 236,000 692,000 — 1.58M — 1.89M — 147,000 —
Interest paid (cash effect) (USD) — 0.00 — — -84,000 — — — — —
Income taxes paid (cash effect) (USD) — — — — — — — — -30,000 —
Share-based compensation (USD) 386,000 1.09M 983,000 — 3.74M — 5.39M — 8.97M —
Operating cash flow before change in receivables (USD) -2.87M -8.12M -10.7M — -36.5M — -19.3M — -82.6M —
Free cash flow (OCF - PPE - intangibles) (USD) -3.25M -7.99M -10.7M — -38M — -72.7M — -95.2M —
Income detail
Research and development expense (USD) 1.43M 2.58M 881,000 — 21.3M — 41.6M — 84.2M —
↳ 5y CAGR +22.0% +21.8%
Total comprehensive income (USD) — — — — -46.5M — -79.3M — -103M —
Comprehensive income to owners (USD) — — — — -46.5M — -79.3M — -103M —
Provision for credit losses (USD) — 0.00 0.00 — 624,000 — — — — —
Credit cost ratio (credit losses / average receivables) (%) — 0.0% 0.0% — 49.4% — — — — —
Reported Sep 27, 2021 Mar 28, 2024 Mar 28, 2024 Aug 11, 2023 Mar 26, 2025 Aug 13, 2024 Mar 26, 2025 Aug 13, 2025 Mar 16, 2026 Aug 10, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

•Updated interim data from the Phase 1/2a bamzireotide navoxetan (VMT-α-NET) presentations continue to support an emerging therapeutic window and potential to achieve a best-in-class profile in NETs

•Meaningful antitumor activity observed for lapemelanotide zapixetar (VMT01) monotherapy in metastatic melanoma to be evaluated with additional patients

•PSV359 received Fast Track Designation from the FDA for FAP-positive solitary fibrous tumors; agreement in place with Merck to support potential evaluation in combination with Keytruda® (pembrolizumab) for certain types of lung and colorectal cancers

•Approximately $202 million in cash, cash equivalents, and short-term investments as of September 30, 2026; expected to be sufficient to fund current planned clinical milestones and operational investments into 2028

SEATTLE – November 9, 2026 – Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced systemic treatments for cancers, today provided a business update and announced results for the quarter ended September 30, 2026.

•Meaningful antitumor activity observed at the 3.0 mCi monotherapy dose with 75% disease control rate and durable disease stabilization; one of two confirmed responders remains on study ~40 weeks after the first treatment

•No dose-limiting toxicities, treatment-related serious adverse events, or discontinuations due to adverse events were reported across 20 patients in three monotherapy dose cohorts as of the data cut-off

•Continued evaluation and dose optimization of lapemelanotide to inform future clinical development

SEATTLE, November 6, 2026 -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced systemic treatments for cancers, today announced updated interim monotherapy results from its ongoing Phase 1/2a clinical trial of [212Pb]lapemelanotide zapixetar (VMT01), an investigational targeted alpha therapy. The Company presented the data as a poster at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting, being held November 4 to 8, 2026, in Phoenix, Arizona.

•Additional analyses presented at NANETS 2026 Multidisciplinary NET Medical Symposium support prior findings of durable ongoing disease control and encouraging responses in all three cohorts across multiple patient populations

•Preliminary evidence of more robust anti-tumor activity and durable responses in GEP-NET patients whose target lesions all express SSTR2+ supports focusing on this population

•Bamzireotide continues to be well-tolerated

•Targeting End-of-Phase 2 meeting in 1Q 2027

SEATTLE, November 5, 2026 -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced systemic treatments for cancers, today announced incremental data and analyses from its ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing neuroendocrine tumors (NETs). These analyses were presented today in an oral presentation at the 2026 North American Neuroendocrine Tumors Society (NANETS) Multidisciplinary NET Medical Symposium taking place November 5-7, 2026 in Las Vegas, Nevada.

Prompts

Perspective Therapeutics, Inc. (ticker CATX), listed in United States.

Company History

Date Change Detail
Feb 21, 2023 Renamed ISORAY, INC. → PERSPECTIVE THERAPEUTICS, INC.
Aug 5, 2005 Renamed CENTURY PARK PICTURES CORP → ISORAY, INC.

ETFs Holding Perspective Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
RESM 0.01% 105 $ 358.05 Jun 30, 2026
DFAS 0.00% 584,598 $ 492.465K Nov 12, 2026
DXUV 0.00% 54,875 $ 46.227K Nov 12, 2026
DFAU 0.00% 32,229 $ 27.15K Nov 12, 2026
DFAC 0.00% 95,830 $ 80.727K Nov 12, 2026
DCOR 0.00% 13,021 $ 10.969K Nov 12, 2026
AVSC 0.00% 138,442 $ 127.893K Nov 16, 2026